Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.388 EUR | +0.09% | -0.93% | -8.10% |
Apr. 25 | Pernod Ricard Sales Fall as It Struggles in China, U.S. -- 2nd Update | DJ |
Apr. 25 | Pernod Ricard Backs Guidance Despite Lower Sales -- Update | DJ |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
Weaknesses
- The company is in debt and has limited leeway for investment
- With a 2024 P/E ratio at 27.53 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- With an enterprise value anticipated at 4.27 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Distillers & Wineries
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.10% | 12.04B | B | ||
-0.96% | 296B | C+ | ||
+8.51% | 81.55B | C+ | ||
+9.34% | 42.47B | D+ | ||
+3.90% | 37.87B | C+ | ||
-8.93% | 20.81B | C+ | ||
+13.62% | 16.62B | C | ||
+7.26% | 10.21B | B- | ||
+21.13% | 10.16B | C- | ||
+4.00% | 7.61B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CPR Stock
- Ratings Davide Campari-Milano N.V.